Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
8.96
+0.19 (2.17%)
At close: May 12, 2025, 4:00 PM
8.97
+0.01 (0.11%)
After-hours: May 12, 2025, 7:25 PM EDT
Viatris Revenue
Viatris had revenue of $3.25B in the quarter ending March 31, 2025, a decrease of -11.17%. This brings the company's revenue in the last twelve months to $14.33B, down -6.71% year-over-year. In the year 2024, Viatris had annual revenue of $14.74B, down -4.46%.
Revenue (ttm)
$14.33B
Revenue Growth
-6.71%
P/S Ratio
0.75
Revenue / Employee
$447,819
Employees
32,000
Market Cap
10.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VTRS News
- 4 days ago - Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars - Benzinga
- 4 days ago - Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade) - Seeking Alpha
- 4 days ago - Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China - Reuters
- 4 days ago - Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook - PRNewsWire
- 4 days ago - Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential - PRNewsWire
- 4 days ago - Viatris' pain drug meets main goals of two late-stage trials - Reuters
- 4 days ago - Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain - PRNewsWire